The Biden administration appoints a new coordinator for its global coronavirus response; more infectious COVID-19 variant first identified in United Kingdom now in all 50 states; spotlighting the impact of COVID-19 on the heart of an athlete.
In an effort to combat growing concerns of vaccine inequity worldwide, the Biden administration announced yesterday the appointment of Gayle Smith, a former director of the US Agency for International Development, to serve as the new coordinator for its global coronavirus response. Reported by The Washington Post, part of Smith’s responsibility will be to mobilize US resources and bolster vaccine production and distribution across the world. Globally, COVID-19 deaths surpassed 3 million today, with Brazil and India currently experiencing significant spikes in cases and deaths.
Reported by CNN, the COVID-19 variant first identified in the United Kingdom, B117, has now been identified in all 50 states, with more than 15,000 cases reported nationwide. Noted as more infectious, and potentially more deadly, existing vaccines have been found to be effective against the variant, although health experts are concerned that the United States may not be able to administer vaccines fast enough to avoid another surge. Cases of the more infectious P.1 COVID-19 variant first identified in Brazil have also been on the rise nationwide, as Massachusetts now accounts for about a quarter of cases of the variant, at 58, followed by Florida’s 55 cases.
In a piece by Kaiser Health News, the impact of COVID-19 on the heart of an athlete was spotlighted. With heart inflammation, known as myocarditis, affecting as many as 1 in 5 people infected with SARS-CoV-2, concern has been noted on whether this could put athletes at risk for lifelong complications and death, particularly if athletes return to play too soon. Although screening studies of collegiate athletes over the past year have found generally lower numbers, authors say that these studies have been too small to provide an accurate measure of how likely athletes are to develop heart issues due to the virus.
Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH
December 6th 2023ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Read More
Humana Report Shows Benefits of Value-Based Care for Patients, Physicians
December 6th 2023Patients seen at value-based care clinics received more preventive screenings and had lower risks of hospitalization and emergency room visits, according to Humana’s 10th annual value-based care report.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH
December 6th 2023ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Read More
Humana Report Shows Benefits of Value-Based Care for Patients, Physicians
December 6th 2023Patients seen at value-based care clinics received more preventive screenings and had lower risks of hospitalization and emergency room visits, according to Humana’s 10th annual value-based care report.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
2 Clarke Drive
Cranbury, NJ 08512